A randomized, double-blind, placebo-controlled phase I trial of inhalation treatment of recombinant TFF2-IFN protein: A multifunctional candidate for the treatment of COVID-19
Background and Objectives: Coronavirus disease 2019 (COVID-19) has caused global pandemics in the last 3 years, and the development of new therapeutics is urgently needed. This study aimed to assess the safety, tolerated, and prolonged retention of recombinant protein trefoil factor 2 (TFF2)- interf...
Main Authors: | Yan Liu, Guanxing Zhai, Weihui Fu, Xiaoyan Zhang, Jianqing Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1063106/full |
Similar Items
-
Validation of the DNA Methylation Landscape of TFF1/TFF2 in Gastric Cancer
by: Ze Qian, et al.
Published: (2022-11-01) -
Trefoil Factor Family (TFF) Peptides
by: Werner Hoffmann
Published: (2021-09-01) -
Porcine Gastric TFF2 is a Mucus Constituent and Differs from Pancreatic TFF2
by: René Stürmer, et al.
Published: (2014-03-01) -
TFF1 Induces Aggregation and Reduces Motility of <i>Helicobacter pylori</i>
by: Daniela Eletto, et al.
Published: (2021-02-01) -
The Forms of the Lectin Tff2 Differ in the Murine Stomach and Pancreas: Indications for Different Molecular Functions
by: Eva B. Znalesniak, et al.
Published: (2023-04-01)